Retrospective Analysis of Racial Differences in Treatment Patterns and Prostate-Specific Antigen Responses Among Patients with Prostate Cancer Treated with Relugolix in the Veterans Health Administration.

ABSTRACT:

Introduction

Relugolix is the only oral androgen deprivation therapy (ADT) approved for advanced prostate cancer (PC). Real-world evidence on treatment patterns and prostate-specific antigen (PSA) responses of relugolix, especially as a function of race, remain limited. This study assessed these outcomes and compared differences between Black and White patients.

Methods

Veterans Health Administration data were analyzed to identify male adults with PC who initiated relugolix between December 2020 and December 2023. Adherence to relugolix was assessed for up to 1 year after treatment initiation and was compared between races using generalized linear models. Discontinuation of relugolix, switching to another ADT, and initiating an add-on PC treatment were assessed using Kaplan-

SUBMITTER: Freedland SJ 

PROVIDER: S-EPMC12618401 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature